indolent non-Hodgkin lymphoma

November 6, 2017

Bayer to Present Long-term Results of Aliqopa in Treating Indolent Lymphomas at ASH 2017

News

Bayer will present long-term safety and efficacy data from the CHRONOS-1 trial of Aliqopa (copanlisib) in patients with indolent lymphomas at the American Society of Hematology (ASH) 2017 Annual Meeting ... Read more

September 18, 2017

Bayer Presents Copanlisib Combination Trials at Scientific Meeting

News

Two Phase 3 trials will assess the potential of Bayer’s copanlisib in combination with other treatment in patients with relapsed indolent B-cell non-Hodgkin’s lymphoma, based on positive data from a ... Read more

May 9, 2017

Verastem to Present Long-term Findings on Duvelisib’s Ability to Counter Non-Hodgkin’s Lymphoma

News

Verastem will present long-term findings on duvelisib’s ability to combat non-Hodgkin’s lymphoma at the 14th International Conference on Malignant Lymphoma in Lugano, Switzerland, June 14-17. Forty-six of 129 lymphoma patients in the DYNAMO Phase 2 clinical ... Read more

May 25, 2016May 25, 2016

Idelalisib for Indolent Non-Hodgkin Lymphoma a Viable Option, Review Finds

News

In a comprehensive review of idelalisib (Zydelig) treatment for patients with indolent non-Hodgkin lymphoma, Hofstra University’s Jacqueline C Barrientos concluded that the drug is a promising option in patients who have already been ... Read more

March 1, 2016May 13, 2016

FDA Approves Gazyva as Combo Treatment for Follicular Lymphomas Unresponsive to Rituxan

News

Genentech announced that the the U.S. Food and Drug Administration (FDA) has approved the combination of Gazyva (obinutuzumab) plus bendamustine chemotherapy followed by Gazyva for the treatment of people with follicular lymphoma who were ... Read more

October 21, 2015October 21, 2015

Infinity Pharmaceuticals Presents Product Updates and Announces 120th Patient Enrolled in DYNAMO Study on Indolent Non-Hodgkin Lymphoma

News

Earlier this month Infinity Pharmaceuticals presented updates on the clinical development and commercial strategy for duvelisib, an oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, during its Research and Development (R&D) Day. The ... Read more